Medical

Tiziana Life Sciences says that after receiving feedback from the FDA following a Type C meeting, the company plans to move forward with a Phase 2 trial of intranasal foralumab, a human anti-CD3 mAb, in… Read more . . .

Avalyn Pharma has published data from its Phase 1b ATLAS study evaluating the safety of AP01 nebulized pirfenidone in patients with idiopathic pulmonary fibrosis over 72 weeks. In the article, the authors report that treatment-related adverse… Read more . . .

Vistagen said that a Phase 3 open label safety study of fasedienol (PH94B, aloradine) nasal spray for the treatment of social anxiety disorder (SAD) found that up to 4 daily doses of 3.2 µg was well-tolerated,… Read more . . .

Firebrick Pharma announced that it is re-starting a Phase 3 clinical trial of Nasodine povidone-iodine nasal spray as the 2023 common cold season begins in the Southern Hemisphere. According to the company, the trial, which… Read more . . .

Aridis Pharmaceuticals has announced that a Phase 2a study of the company’s AR-501 nebulized gallium in cystic fibrosis patients with P. aeruginosa lung infections met its primary and secondary endpoints, with all 3 dose levels tested being well… Read more . . .

ReCode Therapeutics said that it has initiated a Phase 1 clinical trial of its RCT1100 nebulized mRNA-based therapeutic, which the company is developing for the treatment of primary ciliary dyskinesia (PCD) caused by certain genetic… Read more . . .

Iliad Biotechnologies announced that it has published data from a Phase 2b challenge study of its BPZE1 live-attenuated intranasal pertussis vaccine and said that the vaccine induced nasal mucosal and serum immune responses, with 90%… Read more . . .

Armata Pharmaceuticals announced that data from the Phase 1b/2a SWARM-P.a. SAD/MAD study of its AP-PA02 nebulized phage therapy in cystic fibrosis patients with chronic P. aeruginosa lung infections “confirm that AP-PA02 can be effectively delivered to the lungs through… Read more . . .